Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Caribou Biosciences (CRBU) FCF Margin (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed FCF Margin for 6 consecutive years, with 1078.62% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin rose 56832.0% to 1078.62% in Q3 2025 year-over-year; TTM through Dec 2025 was 1538.65%, a 14828.0% decrease, with the full-year FY2024 number at 1390.37%, down 111778.0% from a year prior.
  • FCF Margin was 1078.62% for Q3 2025 at Caribou Biosciences, roughly flat from 1075.85% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1279.38% in Q1 2021 to a low of 1646.94% in Q3 2024.
  • A 5-year average of 810.18% and a median of 846.74% in 2023 define the central range for FCF Margin.
  • Biggest YoY gain for FCF Margin was 62765bps in 2022; the steepest drop was -212007bps in 2022.
  • Caribou Biosciences' FCF Margin stood at 862.6% in 2021, then increased by 20bps to 690.95% in 2022, then increased by 12bps to 604.69% in 2023, then crashed by -154bps to 1534.04% in 2024, then increased by 30bps to 1078.62% in 2025.
  • Per Business Quant, the three most recent readings for CRBU's FCF Margin are 1078.62% (Q3 2025), 1075.85% (Q2 2025), and 1605.06% (Q1 2025).